Tokyo, Oct. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059034) titled 'Assessment of minimal residual disease using droplet digital PCR in cryopreserved ovarian tissue sections from pediatric and adolescent female cancer patients undergoing fertility preservation' on Oct. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Kanagawa Children's Medical Center
Condition:
Condition - Leukemia, malignant lymphoma and other blood disorders, childhood cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - A novel PCR technique is used to detect malignant tumor cells present in ovarian tissue, allowing for the selection of safe ovarian tissue for transplantation.
Basic objectives2 - Safety
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - 18
years-old
>
Gender - Female
Key inclusion criteria - Patients with diseases such as leukemia, blood disorders, or malignant tumors.
Patients for whom informed consent has been obtained from the patient or guardian.
Key exclusion criteria - Cases where consent cannot be obtained.
Other cases that the research director or ethics committee deems inappropriate.
Target Size - 15
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2023 Year 12 Month 19 Day
Date of IRB - 2023 Year 12 Month 21 Day
Anticipated trial start date - 2025 Year 11 Month 01 Day
Last follow-up date - 2029 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067524
Disclaimer: Curated by HT Syndication.
